VIGENCELL
IPOPublic · Seoul, South Korea · Founded 2013
- Headquarters
- Seoul
- Founded
- 2013
- Website
- vigencell.com
- Type
- Public
About
ViGenCell is a biopharmaceutical company developing allogeneic NK-cell and autologous T-cell immune therapies. It combines an in-house GMP facility with a hospital network to pursue clinically focused development and practical therapeutic applications, including programs for rare and refractory diseases. Its core assets include autologous T-cell therapy for hematologic malignancies and CAR-NK-cell development for solid tumors.
Summary
VIGENCELL is a Biotech company based in Seoul, South Korea, founded in 2013.
Tech & App Stack
1 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Aug 2021
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/vigencell"><img src="https://indexed.vc/api/badge/company/vigencell" alt="VIGENCELL on Indexed.vc" width="260" height="76" /></a>